Simcere Pharmaceutical Group Ltd
HKEX:2096
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.03
7.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Simcere Pharmaceutical Group Ltd
Simcere Pharmaceutical Group Ltd
Total Current Liabilities
Simcere Pharmaceutical Group Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Simcere Pharmaceutical Group Ltd
HKEX:2096
|
Total Current Liabilities
¥2.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Current Liabilities
¥6.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Current Liabilities
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
26%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Current Liabilities
¥4.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Current Liabilities
¥13.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Current Liabilities
¥1.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Simcere Pharmaceutical Group Ltd
Glance View
Simcere Pharmaceutical Group Ltd., established in China, navigates the complexities of the pharmaceutical industry with a focus on innovation and accessibility. Emerging as a dynamic player, Simcere embraces a strategy that marries research-driven innovation with pragmatic commercial practices. The company operates a diversified portfolio, prominently featuring pharmaceuticals dedicated to oncology, cardiovascular diseases, and the central nervous system. By maintaining a robust pipeline of new drug candidates while leveraging its existing catalog, Simcere adeptly navigates the challenges of the pharma landscape. Their dedication to research and development is evident, with substantial investment channeled towards creating proprietary medicines that aim to address unmet medical needs and improve patient outcomes. The path to profitability for Simcere hinges on its dual strategy of developing novel therapeutics and forming strategic partnerships. Simcere not only invests heavily in its proprietary R&D but also engages in collaborations with global pharmaceutical enterprises, thus expanding its reach and influence in the global market. The company adeptly manages a sophisticated supply chain to ensure its products are both widely distributed and affordable, adhering to high standards of regulatory compliance in various metropolises. This operational efficiency, coupled with the strategic alliances, allows Simcere to capture significant market share, driving top-line growth and reinforcing its reputation as an innovative leader in the pharmaceutical industry.
See Also
What is Simcere Pharmaceutical Group Ltd's Total Current Liabilities?
Total Current Liabilities
2.7B
CNY
Based on the financial report for Dec 31, 2023, Simcere Pharmaceutical Group Ltd's Total Current Liabilities amounts to 2.7B CNY.
What is Simcere Pharmaceutical Group Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-8%
Over the last year, the Total Current Liabilities growth was -9%. The average annual Total Current Liabilities growth rates for Simcere Pharmaceutical Group Ltd have been -8% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
